Nuvectis Pharma (NVCT) Interest Expenses (2021 - 2026)
Nuvectis Pharma (NVCT) posted Interest Expenses of $1.1 million for Q1 2026, up 6.11% sequentially from $1.0 million in Q4 2025, and down 39.36% YoY from $1.8 million in Q1 2025.
Nuvectis Pharma (NVCT) Interest Expenses (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Interest Expenses for 6 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Interest Expenses fell 39.36% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 39.36% YoY) and the FY2025 annual result came in at $1.0 million, down 94.72% from the prior year.
- Interest Expenses improved to $1.1 million in Q1 2026 per NVCT's latest filing, from $1.0 million in the prior quarter.
- Over five years, Interest Expenses peaked at $19.5 million in Q4 2024 and troughed at $498000.0 in Q3 2025.
- A 5-year average of $5.6 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses surged 1095.54% in 2023, then sank 95.18% in 2024.
- Over 5 years, Interest Expenses stood at $8.6 million in 2022, then jumped by 69.03% to $14.5 million in 2023, then soared by 34.76% to $19.5 million in 2024, then tumbled by 94.72% to $1.0 million in 2025, then rose by 6.11% to $1.1 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $1.1 million, $1.0 million, and $498000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.09 Mn |
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 19.53 Mn |
| Dec 31, 2024 | 19.53 Mn |
| Sep 30, 2024 | 592,000.00 |
| Sep 30, 2024 | 592,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Jun 30, 2024 | 606,000.00 |
| Mar 31, 2024 | 9.64 Mn |
| Mar 31, 2024 | 9.64 Mn |
| Dec 31, 2023 | 14.49 Mn |
| Dec 31, 2023 | 14.49 Mn |